Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
Nat Clin Pract Oncol
; 4(5): 316-21, 2007 May.
Article
en En
| MEDLINE
| ID: mdl-17464339
ABSTRACT
BACKGROUND:
Localized rectal cancer responds well to 5-fluorouracil and radiation-based regimens. A phase I-II trial is currently testing the efficacy of adding bevacizumab, a VEGF-specific antibody, to standard chemoradiotherapy. The case presented here is a complete pathological response seen in a patient with extensive and locally invasive carcinoma after receiving this combined treatment. INVESTIGATIONS Physical examination, rectal ultrasound, PET-CT scan, laboratory tests, proctoscopic examination, chest radiograph, rectal forcep biopsies with immunohistochemistry, and protein and flow cytometric analyses. DIAGNOSIS Large, invasive, ultrasound stage T4 carcinoma of the rectum, which was positive for survivin. MANAGEMENT One 2-week cycle of bevacizumab alone, followed by 3 cycles of bevacizumab with continuous 5-fluorouracil infusion, and external-beam radiation therapy given 5 days per week to the pelvis, abdominoperineal resection with posterior vaginectomy, hysterectomy and bilateral salpingo-oophorectomy.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias del Recto
/
Adenocarcinoma
/
Inhibidores de la Angiogénesis
/
Anticuerpos Monoclonales
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Nat Clin Pract Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2007
Tipo del documento:
Article
País de afiliación:
Estados Unidos